Sanofi: Wholly-owned subsidiary Acetic Anhydride Injection has obtained the drug registration certificate.

Sanofi has announced that its wholly-owned subsidiary, Chengdu Sanofi Biopharmaceutical Co., Ltd., has received the "Drug Registration Certificate" issued by the National Medical Products Administration for acetyl hexapeptide-8 injection. This drug is used for women undergoing controlled ovarian stimulation in assisted reproductive technology to prevent premature luteinizing hormone peak. The acquisition of the registration certificate will further enrich the company's injection product pipeline, helping to enhance its market competitiveness in the field of assisted reproduction. However, the specific sales situation may be affected by factors such as market environment, and have greater uncertainty.